A Study to Evaluate Darvadstrocel in the Treatment of Complex Perianal Fistula in Crohn's Disease Patients

Overview

About this study

The purpose of this study is to evaluate the long-term safety of a single dose of darvadstrocel in participants with Crohn's disease (CD) and complex perianal fistula by evaluation of adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Has participated in and completed the ADMIRE-CD II (NCT03279081) study (i.e., did not discontinue).

Exclusion Criteria:

  • Has been more than 3 months since the participant completed the ADMIRE-CD II study.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Laura Raffals, M.D.

Open for enrollment

Contact information:

Jessica Friton

(507) 284-0495

Friton.Jessica@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20507925

Mayo Clinic Footer